Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial-Reference-Cited by-同舟云学术

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial

Published:2017-11-13 Issue:3 Volume:9 Page:579-586
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Ma Ronald CW¹^ORCID,Del Prato Stefano²,Gallwitz Baptist³,Shivane Vyankatesh K⁴,Lewis-D'Agostino Diane⁵,Bailes Zelie⁶,Patel Sanjay⁶,Lee Jisoo⁷,von Eynatten Maximilian⁷,Di Domenico Maximiliano⁷,Ross Stuart A⁸

Affiliation:

1. Department of Medicine and Therapeutics; The Chinese University of Hong Kong; Hong Kong China

2. Section of Diabetes; Department of Endocrinology and Metabolism; University of Pisa; Pisa Italy

3. Department of Medicine IV; University Hospital Tübingen; Tübingen Germany

4. Department of Endocrinology; Seth G. S. Medical College and KEM Hospital; Mumbai India

5. Boehringer Ingelheim Pharmaceuticals Inc.; Connecticut USA

6. Boehringer Ingelheim Ltd; Bracknell UK

7. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

8. University of Calgary; LMC Endocrinology Centers; Alberta Canada

Funder

Boehringer Ingelheim

Eli Lilly and Company